Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Tavlesse

- PMLiVE

NICE says cost of Dendreon’s cancer vaccine is too high

Another blow as the bankrupt company goes to auction next month

- PMLiVE

NICE set to dismiss Millennium’s Crohn’s drug Entyvio

Body cites uncertain evidence and unlikely value for the NHS

- PMLiVE

NICE rejects pancreatic cancer regimen over cost concerns

Charity says draft decision to deny Abraxane/Gemzar combo is a ‘backwards step’ for the NHS pricing body

NICE rejection of three ovarian cancer drugs stands

Agency will still not recommend Gemzar, Hycamtin and Yondelis for the disease

- PMLiVE

Assessing drugs for ultra-rare conditions in the UK

Alexion’s Soliris has become the first drug to pass through NICE’s new highly specialised technology process

- PMLiVE

NICE backs three ulcerative colitis treatments

Remicade, Simponi and Humira recommended for NHS reimbursement

- PMLiVE

NICE recommends Pradaxa in blood clot indication

Boehringer drug backed to treat and prevent deep vein thrombosis and pulmonary embolism

- PMLiVE

NICE backs Pfizer drug in kidney cancer

Inlyta near end of two-year struggle for recommendation

- PMLiVE

Cancer Drugs Fund is not NICE replacement

Malcolm Qualie, pharmacy lead for specialised services within NHS England, speaks to PMLiVE

- PMLiVE

UK Labour party pledges £330m cancer fund

Says will improve access to cancer drugs, radiotherapy and surgery if elected

UK flag

Education at heart of new UK diabetes guidelines

NICE recommends new standards for adults with type 1 and children with either type 1 or type 2

National Institute for Health and Care Excellence NICE logo

Janssen sways NICE with Stelara discount

UK health watchdog set to recommend drug in psoriatic arthritis after agreeing patient access scheme

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links